Roberts William T.
Known title: Chief Accounting OfficerCIK: 0001852360
Associated companies
Transaction History
| RYTM | ▲ Buy | Option Exercise | 2,500 | — | 3/29/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 912 | $16K | 3/29/2023 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,313 | — | 2/9/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 959 | $27K | 2/9/2023 | View on chart |
| RYTM | ▼ Sell | Open Market | 1,023 | $11K | 3/29/2022 | View on chart |
| RYTM | ▲ Buy | Option Exercise | 2,500 | — | 3/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RYTM: RBC raises price target to $159, maintains Outperform
RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.
RYTM: RBC raises price target to $159, maintains Outperform. RBC Capital kept its Outperform rating on Rhythm Pharmaceuticals and lifted its price target to $159. The new target sits well above the stock’s 52‑week high of $122.20 and higher than the consensus analyst target of $138.59. A recent Benzinga piece also highlighted the stock’s five‑year total return, underscoring its past performance. These developments may influence market perception of the company’s growth prospects.